Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

PURPOSE: R1507 is a selective, fully human, recombinant monoclonal antibody (immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R). The strong preclinical evidence supporting coinhibition of IGF-1R and epidermal growth factor receptor (EGFR) as anticancer therapy prompte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ramalingam, Suresh S., Spigel, David R., Chen, David, Steins, Martin B., Engelman, Jeffrey A., Schneider, Claus-Peter, Novello, Silvia, Eberhardt, Wilfried E.E., Crino, Lucio, Habben, Kai, Liu, Lian, Jänne, Pasi A., Brownstein, Carrie M., Reck, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5320944/
https://ncbi.nlm.nih.gov/pubmed/22025157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.6799
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados